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Abstract
Background: Diabetes is the most common medical condition in pregnant women and its complications affect
both mother and fetus. The beneficial effects of vitamin D on gestational diabetes have been shown, though data
on the effects of co-administration of vitamin D with other nutrients on pregnancy outcomes in gestational
diabetes (GDM) are scarce. This study was aimed to determine the effects of magnesium-zinc-calcium-vitamin
D co-supplementation on parameters of inflammation and oxidative stress, and pregnancy outcomes among
women with GDM.
Methods: This randomized, double-blinded, placebo-controlled trial was conducted on 60 women with GDM
not taking oral hypoglycemic agents. Patients were randomly assigned to take magnesium-zinc-calcium-vitamin D
supplements (n= 30) or placebo (n = 30) for 6 weeks. Fasting blood samples were collected from participants at baseline
and after the 6-week intervention to measure related biomarkers.
Results: Magnesium-zinc-calcium-vitamin D co-supplementation resulted in a significant reduction in serum high-
sensitivity C-reactive protein (− 1.2 ± 3.5 vs. + 0.8 ± 2.0mg/L, P = 0.01) and plasma malondialdehyde concentrations (− 0.3
± 0.3 vs. + 0.3 ± 1.1 μmol/L, P = 0.003), as well as a significant increase in total antioxidant capacity levels (+ 38.2 ± 76.5 vs.
-16.3 ± 93.5mmol/L, P = 0.01), compared to placebo. We found a decreasing trend in newborns’ weight (3089.8 ± 519.9
vs. 3346.3 ± 411.1 g, P = 0.05) and the rate of macrosomia (3.3% vs. 16.7%, P = 0.08) in the magnesium-zinc-calcium-
vitamin D supplemented women.
Conclusions: Overall, the findings of this study have demonstrated that magnesium-zinc-calcium-vitamin D co-
supplementation for 6 weeks to women with GDM may reduce biomarkers of inflammation and oxidative stress.
This study was retrospectively registered on 25 April 2017 in the Iranian website (www.irct.ir) for clinical trials registration
(http://www.irct.ir: IRCT201704225623N109).
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Background
Gestational diabetes mellitus (GDM) is defined as a state
of glucose intolerance that is diagnosed for the first time
during pregnancy [1]. Multiple risk factors, including ges-
tational age, obesity, ethnic background, family history of
type 2 diabetes (T2DM) and a prior history of GDM have
been implicated as the contributors to GDM [2]. The
prevalence of GDM was reported to rates as high as 15–
20% worldwide [3]. In Iran, the prevalence has been as
high as 18.6% [4]. Extra calories and increased weight dur-
ing pregnancy induce inflammatory pathway among
GDM women, which in turn would result in the develop-
ment of insulin resistance and excessive fetal growth;
macrosomia [5]. Moreover, there are evidence suggesting
that underlying factors like obesity enforce oxidative
stress; increased oxidative damage and reduced antioxi-
dant capacity, in women with GDM, which contributes to
the initiation and progression of GDM [6, 7].
Serum levels of magnesium, zinc, calcium and vitamin
D have been reported to be significantly lower in women
with GDM compared to healthy pregnant women [8, 9].
The beneficial effects of single-nutrient supplementation
including magnesium [10], zinc [11], calcium and its
co-administration with vitamin D [12] on attenuating in-
flammation and oxidative stress, and improving pregnancy
outcomes have been proved in women with GDM. How-
ever, to our best knowledge the effects of multinutrients
supplementation (magnesium-zinc-calcium-vitamin D) on
inflammation and oxidative stress markers and pregnancy
outcomes have not been assessed in women with GDM
yet. The synergist immunomodulatory, anti-inflammatory
and antioxidant effects of magnesium, zinc, calcium and
vitamin D [13, 14] might enhance their impact on preg-
nancy outcomes in women with GDM. Same research
team already published that calcium and vitamin D
co-supplementation for 8 weeks diminished inflammation
and oxidative stress markers in women with polycystic
ovary syndrome (PCOS). These effects were more
highlighted rather than supplementing these women with
calcium or vitamin D alone [15].
There are promising evidence suggesting the importance
of different nutrients (magnesium, zinc, calcium, vitamin
D) on inflammation and oxidative stress markers and preg-
nancy outcomes in women with GDM. Therefore, we de-
signed this placebo-controlled trial to determine the
synergistic effects of magnesium-zinc-calcium-vitamin D
co-supplementation on inflammation and oxidative stress
and subsequent pregnancy outcomes among women with
GDM who were not on oral hypoglycemic agents.
Methods
Ethics statements
This study was approved by the Ethics Committee of the
Arak University of Medical Sciences (AUMS). It was
conducted according to the principles explained in the
Declaration of Helsinki. All participants provided written
and informed consent. The present clinical trial was reg-
istered at the Iranian website for registration of clinical
trials (www.irct.ir: IRCT201704225623N109).
Study design and population
This was a prospective, randomized, double-blind,
placebo-controlled trial of women with GDM. This
single-center study was conducted in Arak, Iran between
March and November 2017. Participants were 60
women, aged 18 to 40 years, with GDM who were re-
ferred to the Kosar Clinic in Arak, Iran. Gestational dia-
betes was diagnosed using a “one-step” 2-h 75-g oral
glucose tolerance test (OGTT) at 24–28 weeks’ gestation
and was applied as the inclusion criteria for this trial.
Diagnosis of GDM was based on the American Diabetes
Association guidelines [16]: women whose plasma glu-
cose level met one of the following criteria were consid-
ered as having GDM: fasting plasma glucose level
(FPG) ≥ 92mg/dL, 1 h OGTT≥180 mg/dL and 2 h
OGTT≥153 mg/dL. Exclusion criteria included: history
of placenta abruption, pre-eclampsia, eclampsia, hypo
and hyperthyroidism, kidney or liver diseases, taking
magnesium, zinc, calcium and vitamin D supplements
prior to intervention, being smoker, and insulin therapy
after GDM diagnosis.
Randomization and treatment allocation
At the baseline visit, 60 women with GDM were ran-
domly assigned to receive either 100 mg magnesium, 4
mg zinc, 400 mg calcium plus 200 IU vitamin D supple-
ments (n = 30) or placebo (n = 30) twice a day for 6
weeks. After the termination of intervention at the end
of week 6, all women were monitored for pregnancy out-
comes until the delivery. Supplements and placebos tab-
lets had identical shape and size, and manufactured by
Vitane (Wolfratshausen, Germany) and Barij Essence
Pharmaceuticals (Kashan, Iran), respectively. All study
participants followed the standard pregnancy protocol in
Iran, consuming 1000 IU vitamin D3 and 400 μg/day
vitamin B9, from the beginning of pregnancy, and 60
mg/day ferrous sulfate, from the second trimester. Pa-
tients were requested to come back in order to check
their blood glucose levels weekly (besides their daily
self-monitoring) during the study. In order to improve
the compliance rate, participants received a short mes-
sage on their cell phones as a reminder for supplement
consumption daily. To evaluate the compliance rate,
subjects were asked to bring back the supplement container
at the following visits. To determine the compliance, the
remaining supplements were counted and subtracted from
the amount of supplements provided to the participants.
Moreover, serum magnesium, zinc, calcium and vitamin D
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levels were measured to more assess the compliance rate to
multinutrients supplementation. Study participants were
randomized using computer-generated random numbers.
Randomization and allocation were concealed from the re-
searchers and participants until the final analyses were
completed. The randomized allocation sequence, enrolling
participants and allocating them to intervention groups
were conducted by a trained midwife at the gynecology
clinic. Another person, who was not involved in the trial
and not aware of random sequences, assigned the subjects
to the numbered bottles of capsules. All participants were
requested to maintain their routine dietary habits and phys-
ical activity during the trial. All women completed a 3-day
food record and three physical activity records presented as
metabolic equivalents at weeks 0, 3 and 6 of the
intervention.
Outcomes
In the present study, the primary outcomes were serum
hs-CRP and plasma total nitrite levels. The secondary
outcomes were the biomarkers of oxidative stress and
pregnancy outcomes.
Anthropometric measures
Anthropometric measurements were conducted by a
trained midwife at baseline and the end of the interven-
tion. Weight and height were measured using a Seca 713
scale without shoes and in light clothing to the nearest
0.1 kg and 0.1 cm, respectively. BMI was calculated as
the ratio of the current body weight to height squared
(kg/m2). After labor, all newborns’ weight and length
were measured by a trained midwife using the standard
methods (Seca 155 Scale, Hamburg; Germany). Infants’
head circumference was measured to the nearest 1 mm
with a Seca girth measuring tape. Moreover, we deter-
mined infants’ 1- and 5-min Apgar scores as another
measure of pregnancy outcome.
Clinical measures
Polyhydramnios was diagnosed using the sonographic es-
timation method at the end of the trial. Applying sonog-
raphy, polyhydramnios was detected when amniotic fluid
index (AFI) exceeded 25 cm [17]. Preterm delivery was de-
fined as delivery occurred at < 37 weeks of pregnancy and
newborn’s macrosomia was defined as baby’s birth weight
of > 4000 g. Large-for-gestational-age (LGA) newborns
were live-born infants with their birth weight ≥ 90th per-
centile of birth weight according to the latest normograms
based on gender and gestational age [18].
Biochemical measures
Ten milliliter fasting blood was collected for biomarkers
measurements at weeks 0 and 6 of the intervention.
Serum magnesium, zinc and calcium concentrations were
measured using enzymatic kits (Pars Azmun, Tehran,
Iran), with inter- and intra-assay coefficient variances
(CVs) of less than 5%. To determine FPG, we used enzym-
atic kits (Pars Azmun, Tehran, Iran). Serum
25-hydroxyvitamin D concentrations were measured using
a commercial ELISA kit (IDS, Boldon, UK) with inter- and
intra-assay CVs of 4.6 and 6.4%, respectively. Serum
hs-CRP levels were assessed using ELISA kit (LDN, Nord-
horn, Germany) with intra- and inter-assay CVs of 4.0 and
6.1%, respectively. Part of blood samples were immediately
centrifuged (3000×g, 10min, 4°C) after collection; the
plasma was then separated and stored at -70oC until the
analysis for total nitrite, malondialdehyde (MDA), total
antioxidant capacity (TAC), and GSH. The plasma total
nitrite concentrations were measured using Griess method
[19]; GSH concentrations by the method of Beutler et al.
[20] and MDA levels using thiobarbituric acid reactive
substance spectrophotometric test [21]. Plasma TAC con-
centrations were measured using the ferric reduction anti-
oxidant power method developed by Benzie and Strain
[22]. CVs for plasma total nitrite, TAC, GSH and MDA
were lower than 5%. Newborns’ hyperbilirubinemia was
determined by the total serum bilirubin levels above 15
mg/dL (257 μmol/L) among infants who were 25 to 48 h
old, 18mg/dL (308 μmol/L) in infants who were 49 to 72
h old, and above 20mg/dL (342 μmol/L) in infants older
than 72 h [23].
Sample size calculation
Applying hs-CRP as a primary outcome with a mean
distinction of 3.2 mg/L and a SD of 4.0 mg/L, we used
the standard formula for sample size calculation in clin-
ical trials. Considering a type one error (α) of 0.05 and
type two error (β) of 0.20 with the power of 80%, the cal-
culated sample size was 25 subjects in each treatment
group [24]. Assuming 5 dropouts in each group, the final
sample size was determined to be 30 subjects in each
group.
Statistical analysis
Kolmogorov-Smirnov test was used to check the normal
distribution of data. General characteristics and dietary
intakes were compared between two treatment groups
using an independent-samples t-test. To determine the
effects of magnesium-zinc-calcium-vitamin D on bio-
markers of inflammation and oxidative stress, we used
independent-samples t-test. To control confounding var-
iables including; baseline values, maternal age and base-
line BMI, we used ANCOVA test, using general linear
models. Differences in proportions were assessed using
Chi square test or Fisher’s exact tests. P < 0.05 was con-
sidered as statistically significant. All statistical analyses
were conducted using the SPSS Software (version 18.0,
SPSS Inc., Chicago, Illinois, USA).
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Results
The flow of participants’ recruitment has been demon-
strated in Fig. 1. Sixty participants completed the trial, n
= 30 in magnesium-zinc-calcium-vitamin D arm and n =
30 in placebo arm. Sending daily reminders for supple-
ments consumption, relying on participants’ responds
and by considering that higher than 90% of capsules
were consumed throughout the trial in both groups,
assessed through empty bottles back, we assume that
the compliance rate in the current study was acceptable.
The mean age, height, weight and BMI, at both baseline
and the end of the intervention, were not significantly dif-
ferent between magnesium-zinc-calcium-vitamin D and
placebo groups (Table 1).
Using the 3-day dietary records obtained at baseline,
end-of-trial and throughout the trial, we observed no
significant difference in macro- and micronutrient in-
takes between the two groups during the study (Data
not shown).
Biomarkers of inflammation and oxidative stress at base-
line and after the 6-wk intervention in women with GDM
who received either magnesium-zinc-calcium-vitamin D or
placebo are presented in Table 2. Compared with the
placebo, co-supplementation with magnesium-zinc-cal-
cium-vitamin D significantly increased serum magnesium
(+ 0.1 ± 0.2 vs. -0.05 ± 0.1mg/dL, P = 0.002), zinc (+ 4.1 ±
1.8 vs. + 0.4 ± 2.6mg/dL, P < 0.001), calcium (+ 0.3 ± 0.4 vs.
+ 0.1 ± 0.1mg/dL, P = 0.001) and 25-OH-vitamin D (+ 6.1
± 3.5 vs. + 3.8 ± 1.2 ng/mL, P = 0.001). The co-supplementa-
tion of magnesium-zinc-calcium-vitamin D resulted in a
significant reduction in FPG (− 4.3 ± 4.9 vs. − 0.9 ± 4.5mg/
dL, P = 0.008) and serum hs-CRP (− 1.2 ± 3.5 vs. + 0.8 ± 2.0
mg/L, P = 0.01) and plasma MDA concentrations (− 0.3 ±
0.3 vs. + 0.3 ± 1.1 μmol/L, P = 0.003), and a remarkable in-
crease in TAC levels (+ 38.2 ± 76.5 vs. -16.3 ± 93.5mmol/L,
P = 0.01), compared to placebo.
Newborns’ weight (3089.8 ± 519.9 vs. 3346.3 ± 411.1 g,
P = 0.05) and the rate of macrosomia (3.3% vs. 16.7%, P =
0.08) was lower in the magnesium-zinc-calcium-vitamin
D group compared to the placebo group (Table 3). How-
ever, we did not find a significant difference in the rate of
insulin therapy after intervention, polyhydramnios and
maternal hospitalization. Gestational age, newborn’s
birth size and Apgar scores did not significantly
Randomized (n=60)
Allocated to placebo (n=30)
Lost to follow-up (n=0)
Analyzed (n=30)
Allocated to intervention (n=30)
Lost to follow-up (n=0)
Analyzed (n=30)
Assessed for eligibility among 
GDM women (n=67)
Excluded (n=7) 
- Not meeting inclusion criteria (n=3) 
- Not living in Arak (n=4) 
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Screening for GDM among 
pregnant women (n=750)
Excluded (n=683) 
- Had not GDM (n=675)
- Needed to start insulin therapy (n=8)
Fig. 1 Summary of patient flow diagram
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change following co-supplementation of magnesium-
zinc-calcium-vitamin D.
Discussion
Gestational diabetes poses risks for both mother and fetus.
Pregnant women with obesity or GDM are insulin-resistant
compared to normal pregnant women, which equates to in-
creased maternal inflammation [25]. Suppression of inflam-
mation in these patients helps improving pregnancy
outcomes and maternal complications [26]. Current evi-
dence is suggesting that magnesium-zinc-calcium-vitamin
D co-supplementation has beneficial effects on metabolic
profiles of women with GDM, such as improving insulin
sensitivity and few lipid profiles [27]. We assumed that the
beneficial impacts of multi-nutrients therapy on metabolic
parameters might be related to its attenuating effect on in-
flammatory markers which are the root causes of the meta-
bolic abnormalities. The findings of this study have
demonstrated that magnesium-zinc-calcium-vitamin D
co-supplementation for 6 weeks to women with GDM may
reduce biomarkers of inflammation and oxidative stress.
It must be kept in mind that all pregnant women in
Iran have a monthly check-up meanwhile they are moni-
tored for vitamin D supplements compliant and whether
they have had any side effect with this supplement. In
this study women were compliant with the standard
protocol of pregnancy for vitamin D. Since vitamin D re-
quirement is increased in pregnancy, we added 400 IU to
the combination of other elements and we did not add
more because of risk of side effects as well as we believe
calcium might have synergistic effect with vitamin D.
Observing significant effects in this study moreover
clarifies that although 1000 + 400 IU/day vitamin D
might not be much different from 1000 IU/day in pla-
cebo group, however combination of other helpful nutri-
ents with vitamin D can differentiate the impact of 1000
+ 400 IU/day from 1000 IU/day. However, in the current
study, magnesium levels increased by 0.1mg/dL in the
intervention group, which was statistically significant al-
though might not be clinically significant. The important
point that should be considered is that serum magnesium
concentrations do not thoroughly reflect dietary or sup-
plemental magnesium intake. Although serum magnesium
Table 1 General characteristics of study participants
Placebo group (n = 30) Magnesium-zinc-calcium-vitamin D group (n = 30) P1
Age (y) 29.1 ± 4.1 27.7 ± 4.0 0.19
Height (cm) 163.5 ± 3.7 162.8 ± 4.1 0.48
Weight at study baseline (kg) 67.6 ± 6.1 68.2 ± 9.4 0.78
Weight at end-of-trial (kg) 69.4 ± 6.1 70.0 ± 9.2 0.76
BMI at study baseline (kg/m2) 25.3 ± 2.5 25.8 ± 3.7 0.66
BMI at end-of-trial (kg/m2) 26.0 ± 2.6 26.4 ± 3.6 0.58
Data are means± SDs
1Obtained from independent-samples t-test
Table 2 Biomarkers of inflammation and oxidative stress at baseline and after 6-wk intervention in women with gestational diabetes
who received either magnesium-zinc-calcium-vitamin D or placebo
Placebo group (n = 30) Magnesium-zinc-calcium-vitamin D group (n = 30) P1
Wk0 Wk6 Change Wk0 Wk6 Change
FPG (mg/dL) 95.1 ± 5.4 94.2 ± 5.7 -0.9 ± 4.5 93.1 ± 2.5 88.8 ± 4.7 -4.3±4.9 0.008
Magnesium (mg/dL) 1.7 ± 0.2 1.7 ± 0.2 − 0.05 ± 0.1 1.8 ± 0.1 1.8 ± 0.2 0.1 ± 0.2 0.002
Zinc (mg/dL) 83.9 ± 8.1 84.3 ± 8.1 0.4 ± 2.6 80.3 ± 8.8 84.4 ± 9.1 4.1 ± 1.8 < 0.001
Calcium (mg/dL) 9.1 ± 0.5 9.2 ± 0.5 0.1 ± 0.1 9.1 ± 0.4 9.4 ± 0.4 0.3 ± 0.4 0.001
25-OH-vitamin D (ng/mL) 13.5 ± 3.6 17.3 ± 3.1 3.8 ± 1.2 12.6 ± 4.2 18.7 ± 4.7 6.1 ± 3.5 0.001
hs-CRP (mg/L) 6.3 ± 2.0 7.0 ± 2.6 0.8 ± 2.0 6.9 ± 1.7 5.7 ± 3.7 −1.2 ± 3.5 0.01
Total nitrite (μmol/L) 40.9 ± 10.3 41.2 ± 17.7 0.3 ± 15.3 43.1 ± 5.5 44.3 ± 6.1 1.2 ± 7.1 0.76
TAC (mmol/L) 694.8 ± 111.6 678.4 ± 89.9 −16.3 ± 93.5 619.4 ± 81.1 657.6 ± 98.1 38.2 ± 76.5 0.01
GSH (μmol/L) 475.9 ± 112.0 466.9 ± 109.2 −9.0 ± 96.6 474.2 ± 121.7 486.1 ± 115.6 11.9 ± 63.7 0.32
MDA (μmol/L) 3.0 ± 0.7 3.3 ± 1.3 0.3 ± 1.1 2.9 ± 0.3 2.6 ± 0.2 −0.3 ± 0.3 0.003
All values are means± SDs
1P values represent the time × group interaction (computed by analysis of the repeated measures ANOVA)
FPG fasting plasma glucose, GDM gestational diabetes mellitus, GSH total glutathione, hs-CRP high-sensitivity C-reactive protein, MDA malondialdehyde, TAC total
antioxidant capacity
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levels are dependent on dietary intake, due to difference in
intestinal absorption and kidney function, urinary magne-
sium excretion and intracellular magnesium concentrations
are better indicators for magnesium status than serum mag-
nesium levels. These parameters are also more sensitive to
oral supplementation than serum magnesium concentra-
tions. However, we were not able to assess intracellular
magnesium concentrations in the current study due to
funding limitations. Some investigators have also recom-
mended applying erythrocyte magnesium content to assess
dietary intake [28]. Others have shown that the magnesium
content of white blood cells is a better index of intracellular
magnesium in skeletal and cardiac muscle [28]. Overall, due
to low sensitivity of serum magnesium for assessing magne-
sium status, our results were not clinically significant.
Effects on biomarkers of inflammation and oxidative stress
Elevated hs-CRP is more common among women with
GDM as compared to women with normal pregnancy. A
reference value of hs-CRP levels below 3mg/L is consid-
ered normal [29], and there are a few studies have re-
ported circulating levels of hs-CRP higher than 3mg/L in
women with GDM [30, 31]. Our findings demonstrated
that co-administering of magnesium-zinc-calcium-vitamin
D for 6 weeks to women with GDM attenuated inflamma-
tion and oxidative stress, through decreasing serum
hs-CRP, plasma total nitrite, and MDA levels, and increas-
ing TAC levels. The impact of mono-nutrient therapy has
been depicted in already published clinical trials. We have
previously shown that magnesium oxide (250mg/day)
plus zinc sulfate (220mg/day) co-supplementation for 12
weeks had beneficial effects on hs-CRP and TAC levels,
and gene expression related to IL-1 and TNF-α in women
diagnosed with PCOS [32]. Consistent with our results,
co-administration of calcium (1000mg/day) with vitamin
D (50,000 IU/week) supplements for 12 weeks has been
shown to significantly lessen systemic inflammation,
through decreasing IL-6 and TNF-α levels in patients with
T2DM [33]. Moreover, among young men with sedentary
lifestyle, magnesium supplementation for 4 weeks had re-
markable impacts on diminishing DNA oxidative damage
[34]. In another study, taking zinc gluconate by obese in-
dividuals, at a dosage of 30mg/day, for 8 weeks resulted in
a significant reduction in serum hs-CRP concentrations
[35]. Elevated inflammatory cytokines and oxidative stress
during pregnancy contribute to increased cardiovascular
risk [36] and insulin resistance post-partum [31, 37].
Anti-inflammatory effects of magnesium, vitamin D and
zinc may be due to their antagonistic impact on serum
calcium [31, 38] and their role in regulating nuclear
factor-κB activity, and peroxisome proliferator activated
receptor-α signaling pathway, which require zinc and
magnesium for their anti-inflammatory effects [39]. In
addition, less production of parathyroid hormone fol-
lowing the intake of calcium and vitamin D supple-
ments may result in the reduced production of
inflammatory factors [40]. Magnesium and zinc intake
might reduce oxidative damage through decreasing
ROS production [41] and decrease the formation of
·OH from hydrogen peroxide by counteracting the
redox-active transition metals [42]. Furthermore, anti-
oxidant impact of vitamin D might be explained by a
significant decrease in ROS and pro-inflammatory
markers [43].
Table 3 The association between magnesium-zinc-calcium-vitamin D co-supplementation and pregnancy outcomes
Placebo group (n = 30) Magnesium-zinc-calcium-vitamin D group (n = 30) P1
Cesarean section (%) 9 (30.0) 4 (13.3) 0.11†
Preterm delivery (%) 1 (3.3) 0 (0.0) 0.31†
Need to insulin therapy after intervention (%) 2 (6.7) 1 (3.3) 0.55†
Pre-eclampsia (%) 3 (10.0) 2 (6.7) 0.64†
Polyhydramnios (%) 2 (6.7) 1 (3.3) 0.55†
Macrosomia > 4000 g (%) 5 (16.7) 1 (3.3) 0.08†
Gestational age (weeks) 39.2 ± 1.1 39.1 ± 1.2 0.90
Newborns’ weight (g) 3346.3 ± 411.1 3089.8 ± 519.9 0.05
Newborns’ length (cm) 50.0 ± 1.4 49.2 ± 3.6 0.28
Newborns’ head circumference (cm) 35.2 ± 1.7 34.4 ± 3.0 0.20
1- min Apgar score 8.8 ± 0.4 8.9 ± 0.3 0.45
5- min Apgar score 9.8 ± 0.4 9.9 ± 0.3 0.45
Newborns’ hyperbilirubinemia (%) 12 (40.0) 8 (26.7) 0.27†
Newborns’ hospitalization (%) 12 (40.0) 8 (26.7) 0.27†
Values are means± SDs for continuous measures and are number (%) for dichotomous variables
1Obtained from independent t-test
†Obtained from Pearson Chi-square test
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Effects on pregnancy outcomes
Additional demands associated with pregnancy and fetal
growth, pose pregnant women at more risk for multiple
nutrient deficiencies [44]. The results of current study re-
vealed a decreasing trend in newborns’ weight and the rate
of macrosomia in the magnesium-zinc-calcium-vitamin D
co-supplemented group compared to the placebo group.
Following supplementation, the difference between birth
weights was large and non-significant between interven-
tion groups (3089.8 vs. 3346.3, P = 0.05). This result has
been presented as mean values, however when we
assessed data of birth weight individually we did not see
any birth weight below normal value. On the other hand,
the reduction in macrosomia rate was one of the goals of
this study. Overall, based on current findings we did not
consider these reductions as negative effects. Same re-
search group has already shown that magnesium supple-
mentation might decrease the incidence of newborn
hyperbilirubinemia and newborn hospitalization and was
less associated with macrosomia [10]. Looking at the effect
of zinc on pregnancy outcomes, the results are inconclu-
sive, which might be related to high incidence of zinc defi-
ciency in pregnancy and low doses of supplementation are
usually used in different trials [45, 46]. The combination
of vitamin D and calcium has been shown significant re-
duction in the rate of macrosomia and caesarean section
in women with GDM [12]. The inconclusive results in the
current trial, as a multi-nutrients supplementation ap-
proach might be related to the following parameters; sup-
plementation strategies might be beneficial when a
deficiency is observed, maternal weight gain during preg-
nancy is of major importance and is affected by different
factors like woman’s age, environmental conditions, diet,
socioeconomic status and psychological parameters,
higher doses of nutrients might be required to see any ef-
fect on pregnancy outcomes [47].
The current study had a few limitations. The sample size
was not large enough to detect more detailed outcomes
changes following supplementation. Six weeks of interven-
tion might not be long enough to determine any changes
resulted from multi-nutrients supplementation. Therefore,
future studies with longer duration of the intervention,
and larger sample sizes are needed to confirm our find-
ings. In addition, we did not determine the effects of
magnesium-zinc-calcium-vitamin D co-supplementation
on all of the pregnancy outcomes including the infant re-
spiratory status and the duration of neonatal intensive
care, as well as the gene expression related to inflamma-
tion and oxidative stress. We were not able to assess intra-
cellular magnesium concentrations in the current study
due to funding limitations. However, TAC levels are evalu-
ated using FRAP assays. Since hemoglobin data were not
available in this study, we were not able to adjust our re-
sults based on circulating hemoglobin levels. This should
be considered in the interpretation of our findings. In
addition, we did not evaluate the sensitivity of plasma total
nitrite concentrations using Griess method.
Conclusions
Overall, the findings of this study have demonstrated that
magnesium-zinc-calcium-vitamin D co-supplementation
for 6 weeks to women with GDM may reduce biomarkers
of inflammation and oxidative stress.
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